Codiak BioSciences, Inc.
codiakbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 3, 2022. Its latest SEC filing is a SC 13G/A from Feb 14, 2024.
10-Q for Q3 FY2022, filed Nov 3, 2022
The sections below describe the company as of the FY2021 annual report.
What Did They Do?
Develops engineered exosome drug candidates for cancer, infectious disease and rare disease.
10-K for FY2021, filed Mar 10, 2022
How Did They Make Money?
Partners pay Codiak through upfront collaboration fees and reimbursements for work; it may also receive milestone payments when specified events occur, royalties when licensees sell products, and profit shares from products it co-commercializes.
10-K for FY2021, filed Mar 10, 2022
$22.9M
-
10-K for FY2021, filed Mar 10, 2022
$22.9M ↗
Who Were Their Customers?
Jazz collaborates with Codiak on exosome therapeutics; Lonza is its manufacturing partner and holds a license to Codiak’s manufacturing intellectual property.
10-K for FY2021, filed Mar 10, 2022
Did Revenues Turn Into Profits?
No. It lost $37.2M in FY2021.
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2022, filed Nov 3, 2022
−$19.3MView ↗
- ▼ −11% (Loss)
- vs −$21.7M in Q3 FY2021
-
Mar 29, 2023
Nasdaq moves to delist Codiak’s securities
Trading was scheduled to be suspended following the company’s bankruptcy filing.
Sources
8-K, filed Mar 29, 2023
As previously reported, on March 27, 2023, Codiak BioSciences, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11…View ↗
-
Mar 27, 2023
Files for bankruptcy and plans to sell substantially all assets
Codiak continues operating under court supervision while pursuing an asset sale; its CEO and CFO are also leaving.
Sources
8-K, filed Mar 27, 2023
On March 27, 2023, Codiak BioSciences, Inc. (the “Company”) filed a voluntary petition (the “Bankruptcy Petition”) for relief under Chapter…View ↗
Who Did They Compete With?
Competes with Aegle Therapeutics, ArunA, Capricor Therapeutics, ReNeuron Group, AstraZeneca, Evox Therapeutics, PureTech Health, Bristol Myers Squibb, Merck, Takeda Pharmaceutical, Eisai, Nimbus Therapeutics, GlaxoSmithKline, F-star, Synlogic, Mavupharma, Astellas Pharma, Celsion, Cytix, and Dragonfly Therapeutics
10-K for FY2021, filed Mar 10, 2022Unmodified cell-derived exosomes generally rely on the intrinsic therapeutic activity of cargo in exosomes collected from a specific…View ↗
Loading...
